Eledon Pharma Reports Improved Quality Of Life And Reduced Symptom Burden With Tegoprubart In Kidney Transplant Patients At ASN Kidney Week 2026

Tegoprubart-treated patients demonstrated a mean improvement on the total MTSOSD-59R symptom occurrence scale at 12 months while tacrolimus-treated patients experienced a mean worsening of symptom occurrence

Statistically significant improvement on the KDQOL-SF Symptoms and Problems Scale among tegoprubart-treated patients through 12 months following kidney transplantation versus tacrolimus

Results further validate the differentiated clinical profile of tegoprubart and potential to transform standard of care in kidney transplantation

IRVINE, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced new positive patient-reported outcomes data from the Phase 2 BESTOW clinical trial of tegoprubart, its novel investigational immunosuppression therapy. The data showed significant, sustained improvements in health-related quality of life and symptom burden through 12 months compared with standard of care tacrolimus following kidney transplantation. The results were featured in an oral presentation at the American Society of Nephrology (ASN) Kidney Week 2026 Annual Meeting held October 21-25, 2026, in Denver, Colorado.